Table 2.

Mutational Activation of the PI3K and RAS Pathways Is Mutually Exclusive in Human Breast Cancer Cell Lines

Breast Cancer Cell LinesPTENPIK3CAKRASBRAFHRASNRAS
BT549V275X
CAMA-1D92H
EVSA-TT319X
HCC1937no protein
MDA-MB-415C136Y
MDA-MB-468A72fsX5
ZR-75-1L108R
MDA-MB-453E307KH1047R
BT20P539R/H1047R
MDA-MB-361E545K/K567R
BT474K111N
BT483E542K
MCF-7E545K
OCUB-FH1047R
SK-BR-5H1047R
SUM102PTH1047R
SUM185PEH1047R
SUM190PTNAH1047R
T47DH1047R
UACC893H1047R
SUM159PTH1047LG12D
Hs578TG12D
SK-BR-7G12CQ61R
MDA-MB-134VIG12R
MPE600G12V
SUM229PEG12D
MDA-MB-231G13DG464V
MDA-MB-435sV600E
DU4475V600E
ZR-75-30I326T
MDA-MB-157
MDA-MB-175VII
MDA-MB-330
MDA-MB-436
SK-BR-3
SUM149PT
SUM225CWNNANA
SUM1315MO2
SUM52PE
UACC812
Mutation rate8 of 38 (21%)14 of 39 (36%)5 of 40 (13%)4 of 40 (10%)2 of 40 (5%)1 of 40 (3%)
  • NOTE: Overview of mutations that were identified in 40 human breast cancer cell lines. The mutations are detailed in Table 1.

  • Abbreviation: NA, not analyzed.